Research programme: immuno-oncology therapies - FLX Bio

Drug Profile

Research programme: immuno-oncology therapies - FLX Bio

Alternative Names: CCR4 inhibitors - FLX Bio; MDSC inhibitors - FLX Bio; Myeloid-derived suppressor cell inhibitors - FLX Bio; Regulatory T-cell inhibitors - FLX Bio

Latest Information Update: 17 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FLX Bio
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action CCR4 receptor antagonists; Regulatory T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Apr 2017 Pharmacodynamic data from preclinical studies in Cancer presented at the 108th Annual meeting of the American Association of Cancer Research (AACR-2017)
  • 01 Jan 2017 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top